# Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

Study · id `cardio:ct-nct03490097` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03490097](<https://clinicaltrials.gov/study/NCT03490097>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03490097

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03490097. Randomized; double masking; primary purpose treatment. Start 2017-12-01 (actual); primary completion 2018-05-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03490097, source copy `cardio:ctgov-nct03490097-2018-09-20`, retrieved 2026-10-31)
- Started: 2017-12-01 (actual) (ClinicalTrials.gov record NCT03490097, source copy `cardio:ctgov-nct03490097-2018-09-20`, retrieved 2026-10-31)
- Primary completion: 2018-05-23 (actual) (ClinicalTrials.gov record NCT03490097, source copy `cardio:ctgov-nct03490097-2018-09-20`, retrieved 2026-10-31)
- Completion: 2018-05-23 (actual) (ClinicalTrials.gov record NCT03490097, source copy `cardio:ctgov-nct03490097-2018-09-20`, retrieved 2026-10-31)
- Countries: Egypt (ClinicalTrials.gov record NCT03490097, source copy `cardio:ctgov-nct03490097-2018-09-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03490097-2018-09-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
- Condition: Chronic Hepatitis c
- Condition: Metabolic Syndrome
- Intervention (Drug): Simvastatin 10mg
- Intervention (Drug): sofosbuvir plus daclatasvir
- Lead sponsor: Ain Shams University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry lists this organization as the lead sponsor: Ain Shams University (`cardio:org-ain-shams-university`)

## Provenance

Content hash: 4a856328e96952ffe0edc35268d1a29367c70c759ef533021bc6ec029bf7243d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
